KaloBios Pharmaceuticals Inc (KBIO.OQ)

KBIO.OQ on NASDAQ Stock Exchange Global Market

17 Apr 2015
Change (% chg)

$-0.01 (-2.22%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for KBIO.OQ


KaloBios Pharmaceuticals, Inc. is a company biopharmaceutical company focused on the development of monoclonal antibody therapeutics. Its pipeline is comprises of three Humaneered antibodies: KB001-A, KB004 and KB003. KB001-A is a Humaneered, PEGylated, anti-PcrV modified antibody fragment (Fab) antibody, being developed for the... (more)


Beta: --
Market Cap(Mil.): $18.55
Shares Outstanding(Mil.): 32.92
Dividend: --
Yield (%): --


  KBIO.OQ Industry Sector
P/E (TTM): -- 155.83 41.17
EPS (TTM): -1.15 -- --
ROI: -82.38 -1.02 16.08
ROE: -89.25 -2.93 16.92
Search Stocks

KaloBios drops lung infection drug, shares plunge

Jan 6 - KaloBios Pharmaceuticals Inc said it would discontinue the development of its drug for lung infections in cystic fibrosis patients after it failed in a mid-stage study, wiping off more than half of its market value.

06 Jan 2015


  Price Chg
Takeda Pharmaceutical Co Ltd (4502.T) ¥6,095 +69.00
Pfizer Inc. (PFE.N) $35.04 -0.15
Novartis AG (NOVN.VX) CHF97.20 -1.85
Roche Holding Ltd. (ROG.VX) CHF270.20 -5.10
Amgen, Inc. (AMGN.OQ) $163.58 -3.29

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
Provider: Thomson Reuters Stock Report
Provider: ValuEngine, Inc.
Provider: Ford Investor Services, Inc.
Provider: ValuEngine, Inc.

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks